Recently, Beijing GeneCradle Technology Co., Ltd. (hereinafter referred to as "GeneCradle") announced that it has received tens of millions of yuan in additional rounds of financing after the recent pre-B round of financing of 100 million yuan. The additional round was exclusively invested by Guoke Jiahe.

Beijing GeneCradle Co., Ltd. was established in 2018. With the quality policy of "originating from demand, courageous innovation, dedicated to design, strict verification, sophisticated manufacturing, and benefiting patients", it has developed a variety of gene therapy drugs for rare diseases, chronic diseases and degenerative diseases. Among them, gene drugs for spinal muscular atrophy type 1, 2, and 3, early-onset and late-onset Pompe disease, and hypertriglyceridemia with acute pancreatitis have all been approved by the National Medical Products Administration for clinical trials.

At present, there are more than 7,000 known rare diseases in the world. Although the total incidence of rare diseases is relatively low, rare diseases are not actually "rare" in China due to the large population base in my country. At present, the treatment of rare diseases in China mainly relies on imported and generic drugs, and there is a general dilemma of "drugs are available abroad, but not in China". Special drugs for the treatment of rare diseases orphan drugs in China are even more scarce. Since the vast majority of rare diseases are caused by gene mutations, gene therapy can achieve more accurate and effective long-term targeted treatment by supplementing the missing gene fragments, improving the survival status of patients from the source of the disease. At present, 7 AAV gene therapy drugs for rare diseases have been approved for marketing abroad, while this field is still blank in China. GeneCradle focuses on the R&D, innovation and manufacturing of gene therapy drugs in the fields of hereditary neuromuscular diseases, hereditary metabolic diseases, lysosomal diseases and ophthalmic diseases. The positioning of pipeline products is based on clinical needs. At present, many AAV gene drugs developed by the company have been clinically tested in multiple clinical research centers such as the Seventh Medical Center of the General Hospital of the Chinese People's Liberation Army, Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences, Peking University First Hospital, the First Medical Center of the General Hospital of the Chinese People's Liberation Army and Beijing Tiantan Hospital affiliated to Capital Medical University. Together with clinical units and related cooperative units, we have promoted the entry of rare disease gene therapy drugs with independent intellectual property rights into the clinic and market. Mr. Zhang Wei, partner of Guoke Jiahe, said that GeneCradle has mastered the international leading technology for the efficient production of AAV vectors, the core of gene therapy drugs, and has fully considered clinical needs and disease pathogenic mechanisms in the way of administration, and designed and developed a series of independent and innovative gene therapy pipelines. The company's first gene drug for spinal muscular atrophy (SMA) uses intrathecal injection, which significantly reduces the amount of AAV used for treatment, and the progress of clinical trials is leading in China. The R&D platform has gene therapy drugs for multiple indications such as Pompe disease, which have differentiated competitive advantages and help my country maintain world-class level and competitiveness in this advanced biopharmaceutical industry. As a science and technology innovation private equity fund management institution initiated and established by Guoke Holdings, Guoke Jiahe is honored to participate in this round of financing of GeneCradle. Guoke Jiahe will actively promote the company's advanced gene therapy technology to exert greater market effects through the international cooperation network among first-class scientific research institutes through the enabling advantages of "technical capital".

About CAS Capital

CAS Capital (Beijing) Investment Management Co., Ltd. was established in 2011. It is a science and technology innovation private equity fund management institution initiated and established by the Chinese Academy of Sciences Holding Co., Ltd. (hereinafter referred to as "CAS Holding") as a cornerstone investor. It is a first-level enterprise managed by CAS Holding. In the twelve years since its establishment, CAS Capital has always played a leading role in the investment of "technology capital" in the field of hard technology. Relying on the first-class technical capabilities of scientific research institutes, a large number of high-tech transformation results, and government and industry resources, it has accumulated in-depth industry understanding of hard technology and rich investment practice experience, and has invested in more than 100 high-tech innovative enterprises with technological barriers in the fields of big data, cloud computing, intelligent manufacturing and high-end equipment, network security and enterprise services, semiconductors, artificial intelligence, medical services, innovative drugs and medical devices.

About GeneCradle

Beijing GeneCradle Technology Co., Ltd. is a national high-tech enterprise with AAV vector delivery technology-mediated gene therapy drug development as its core business. Its mission is to promote China's rare disease gene drugs from basic to clinical and market, benefiting patients and families. The company focuses on the development of gene therapy drugs in the fields of hereditary neuromuscular diseases, genetic metabolic diseases, lysosomal diseases and ophthalmic diseases. By promoting the development and clinical application of rare disease gene drugs, it has a deeper understanding of life and health, and has transitioned gene therapy technology and products from rare diseases to the treatment and rehabilitation of chronic diseases and other major diseases.